2024第一三共DS-8201专利调研实务指南报告

Investment Rating - The report does not explicitly state an investment rating for the industry or the specific product DS-8201. Core Insights - The report focuses on the patent research process for the antibody-drug conjugate (ADC) DS-8201, highlighting its clinical significance and market potential. DS-8201, also known as trastuzumab deruxtecan, received approval from the Chinese National Medical Products Administration in February 2023 and has shown promising sales figures, reaching $879 million globally in Q1 2024, an increase of $348 million compared to the same period in 2023 [11]. Summary by Sections Introduction - The report is a collaboration between the Wisdom芽 Biopharmaceutical team and HANKUN Law Firm, providing a practical guide for patent research on ADC drugs, specifically focusing on DS-8201 [3]. Chapter 1: ADC Patent Research Process - The report outlines a systematic approach to patent research for ADC drugs, utilizing the Wisdom芽 New Drug Intelligence Database to gather foundational information and identify core patents [9]. Chapter 2: DS-8201 Patent Research Practices - 2.1 Introduction to DS-8201: DS-8201 is a novel ADC targeting HER2, effective against both HER2-positive and certain HER2-low expressing tumors, with significant clinical applications in various cancer types [11]. - 2.2 Basic Information Retrieval: The report details the process of retrieving basic information about DS-8201 from the Wisdom芽 New Drug Intelligence Database [12]. - 2.3 Initial Patent Search: A total of 26 related patents were identified, with four core patents selected for further analysis based on their relevance to DS-8201 [15]. - 2.4 Core Patent Analysis: The analysis of core patents revealed structural details of the components of DS-8201, confirming the alignment of the patents with the drug's composition [21]. - 2.5 Component Patent Identification: The report describes the process of identifying original patents for the components of DS-8201, including the toxin DXD, antibody trastuzumab, and linker [23][26][27]. - 2.6 Comprehensive Patent Layout: A detailed analysis of all related patents was conducted to create a patent layout for DS-8201, categorizing them by application time and legal status [29].